Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 4/20 | 0.49 |
| ▸ | DPP4 | P27487 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | F2 | P00734 | 3/20 | 0.42 |
| ▸ | XIAP | P98170 | 1/20 | 0.42 |
| ▸ | MLX | Q9UH92 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CMA1 | P23946 | 1/20 | 0.40 |
| ▸ | ACE | P12821 | 2/20 | 0.40 |
| ▸ | TACR1 | P25103 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | CTSG | P08311 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18100584 | 1.00 | ELANE (0.49) | ELANEDPP4GAAF2XIAP | |
| SCHEMBL20747589 | 1.00 | ELANE (0.49) | ELANEDPP4GAAF2XIAP | |
| SCHEMBL30814203 | 0.91 | ELANE (0.48) | ELANEDPP4GAAF2XIAP | |
| SCHEMBL16703831 | 0.91 | ELANE (0.48) | ELANEDPP4GAAF2XIAP | |
| SCHEMBL30814176 | 0.91 | ELANE (0.48) | ELANEDPP4GAAF2XIAP | |
| SCHEMBL20859027 | 0.91 | ELANE (0.48) | ELANEDPP4GAAF2XIAP | |
| SCHEMBL20853469 | 0.91 | ELANE (0.48) | ELANEDPP4GAAF2XIAP | |
| SCHEMBL16703830 | 0.91 | ELANE (0.48) | ELANEDPP4GAAF2XIAP | |
| SCHEMBL16703327 | 0.91 | ELANE (0.48) | ELANEDPP4GAAF2XIAP | |
| Hydrochloric Acid SCHEMBL18094983 | 0.90 | ELANE (0.48) | ELANEDPP4GAAF2XIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10207994-B2 | NMDA antagonist prodrugs | ASTRAZENECA AB (SE) | 2019-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10207994-B2 | NMDA antagonist prodrugs | GRIN1, GRIN2A, GRIN3A | ELANE 2956/4885DPP4 1168/4885GAA 3289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.